Nathan D. Lakey, MBA, President and Chief Executive Officer

Mr. Lakey is President and Chief Executive Officer and a member of the Board of Directors. He was regionally recognized with the top 40 under 40 award (2004 St. Louis), presented with the governor's top technology award (2005 Missouri) and currently serves on the Patient Care Committee of the Board of Missouri Baptist Hospital. Mr. Lakey was founding principal of Orion Genomics where he has served as President and Chief Executive Officer since June 2000. Mr. Lakey has more than 20 years of experience in genomics. Prior to the founding of Orion Genomics, he was Director of DNA Sequencing at Millennium Pharmaceuticals, Inc., in Cambridge, Massachusetts (1994-98), where he built and operated the DNA sequencing platform for Millennium and helped form three strategic business units - Millennium Predictive Medicine, Millennium Biotherapeutics and Cereon Inc. Before joining Millennium, Mr. Lakey held various positions with Molecular Dynamics (Sunnyvale, CA), Ambion Inc (Austin, TX) and Harvard Medical School, Department of Genetics, in the laboratory of George Church. Mr. Lakey received a B.A. in Biochemistry from the University of Texas (Austin), and an MBA from Washington University Olin School of Business (St. Louis) where he received the C. William Emory Executive MBA Award. Mr. Lakey holds 3 issued US patents and multiple pending applications.

Jared M. Ordway, Ph.D., Vice President of Research and Development

Jared Ordway, Ph.D. is Director of Research and Development at Orion Genomics. Since joining Orion Genomics in 2004, he has participated in the development and validation of a novel comprehensive DNA methylation profiling technology and has applied this technology to the successful discovery of powerful DNA methylation-based biomarkers for various cancers. Dr. Ordway received his Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham where his work was focused on the development and characterization of gene-targeted mouse models of neurodegenerative diseases caused by CAG repeat expansion mutations, including Huntington's Disease, Kennedy's Disease, and the spinocerebellar ataxias. He completed his Postdoctoral Fellowship at St. Jude Children's Research Hospital in Tom Curran's laboratory, where his research focused on the role of DNA methylation in oncogenic transformation and brain tumorigenesis.

Steven Smith, Vice President of Bioinformatics

Mr. Smith serves as Vice President of Bioinformatics at Orion Genomics. Prior to joining Orion Genomics in December 2010, he was Vice President of Bioinformatics at NimbleGen Systems Inc. (2001-2007) and owner of Genesmith Informatics LLC, a consulting firm to the biotechnology sector (2000 - 2010). From 1994 to 2000, Mr. Smith worked for the Wisconsin-based Genetics Computer Group, where he was the Manager of Research and Development. Mr. Smith was the Director of Computation at the Harvard Genome Laboratory (1990-1992) where he led the assembly and analysis of the Mycoplasma capricolum genome under the direction of Walter Gilbert. He was a research programmer in the laboratory of Carl Woese at the University of Illinois at Champaign-Urbana where he holds a B.S. in computer science from the School of Engineering.